Case report: continued treatment with alectinib is possible for patients with lung adenocarcinoma with drug-induced interstitial lung disease

Case report: continued treatment with alectinib is possible for patients with lung adenocarcinoma with drug-induced interstitial lung disease

Abstract Background Alectinib, a second-generation anaplastic lymphoma kinase (ALK) inhibitor, is a key drug for ALK rearranged lung adenocarcinoma. Interstitial lung disease (ILD) is an important adverse effect of alectinib, which generally requires termination of treatment. However, we treated two...

Full description

Bibliographic Details
Main Authors: Tatsuya Nitawaki, Yoshihiko Sakata, Kodai Kawamura, Kazuya Ichikado
Format: Article
Language:English
Published: BMC 2017-12-01
Series:BMC Pulmonary Medicine
Subjects:
Lung cancer
Non-small cell lung cancer
ALK
Alectinib
Interstitial lung disease
GGO
Online Access:http://link.springer.com/article/10.1186/s12890-017-0519-y

Internet

http://link.springer.com/article/10.1186/s12890-017-0519-y

Similar Items